BioCardia wants to gauge whether it has enough evidence to pursue regulatory approval for CardiAMP in ischemic heart failure.

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

Experts don't back specific tests, but provide guidelines on how doctors in specialty care settings can use them to diagnose ...

Neurologists from multiple clinics shared data at AAIC on the Alzheimer's drug's use, shedding light on its safety and ...

The therapies, which are just starting to enter clinical trials, will need to prove clear clinical and quality-of-life ...

The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific ...

Despite regulatory setbacks, the petitioners believe that survival and other data they've collected themselves are worth ...

Trontinemab is a formulation of Roche's failed gantenerumab but now paired with the company's Brainshuttle technology to ...

Blood Cancer UK is launching early career grants following a tough pandemic-era funding climate, while US funders worry about ...

As Keytruda generic competition looms larger on the horizon, the company is hoping to reinvest the savings into pipeline ...

The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.

In a new paper, a team from Yale and Fred Hutch has found autoantibody reactivity could predict cancer patients' response to ...